Materials • Major Chemicals
$514.24 ▲ +11.09
(+2.20%)
MKT CAP: $231.94B • VOL: 3.12M
52W L $388 52W H $548
LIN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $33.99B | $33.01B | $32.85B |
| YoY Revenue Growth % | +3.0% | +0.5% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $8.92B | $8.63B | $8.02B |
| Operating Margin % | 26.3% | 26.2% | 24.4% |
| Net Income (GAAP) | $6.90B | $6.57B | $6.20B |
| EBITDA (Normalized) | $13.13B | $12.23B | $9.21B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $10.35B | $9.42B | $9.30B |
| Capital Expenditures (CapEx) | $5.26B | $4.50B | $1.48B |
| Free Cash Flow (FCF) | $5.09B | $4.93B | $7.83B |
| FCF Margin % | 15.0% | 14.9% | 23.8% |
| Return on Invested Capital (ROIC %) | 13.1% | 14.0% | 8.2% |
| Cash & Short-Term Equivalents | $5.06B | $4.85B | — |
| Total Debt (Short + Long Term) | $20.68B | $15.34B | $29.85B |
| Total Stockholders' Equity | $38.24B | $38.09B | $61.23B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR LIN.